Tesamorelin turns up in training conversations as a growth hormone releasing analogue, usually framed as a leaner, better tolerated route to what exogenous GH is supposed to do. The framing skips the most useful fact about it: this compound has an approved label, and the label is specific.
What is approved, and for whom
Tesamorelin is FDA approved as EGRIFTA, now EGRIFTA SV, under BLA 022505, held by Theratechnologies. It is a prescription product, supplied as a powder for reconstitution.
The approved indication reads: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label also carries a limitation of use stating that long-term cardiovascular safety has not been established.
That is one population and one outcome. Not body composition in trained adults, not recovery, not lean mass.
Why an approved label changes what a chart means
For most compounds on this site there is nothing to restate. The animal literature specifies amounts per kilogram of rodent, and those figures do not convert. A dosage chart in that situation can only report what a study did or what a seller suggests.
Tesamorelin is different. A tesamorelin dosage chart can restate quantities a regulator reviewed, and that is a materially stronger provenance than anything available for BPC-157 or MOTS-c.
The catch is that the authorisation is attached to the indication. Quantities approved for reducing visceral fat in HIV-associated lipodystrophy were studied in that population, for that endpoint. Lifting the number out and applying it to a different goal in a different population is extrapolation, and it looks exactly like reporting once it is in a table.
The lean mass question, answered honestly
A GHRH analogue that reduces visceral adipose tissue in a specific clinical population is not the same claim as a compound that builds or preserves lean mass in a trained one. The label describes the first. Nothing in it describes the second, and the trial programme, 24 registered studies under the name, was not designed to answer it.
That is a more useful position than either dismissal or endorsement. The compound is real, approved and studied. It is approved for something that is not what most people asking about it want.
Reading any chart for it
Two checks. Does the chart state the approved indication alongside the quantities, or present figures with no population attached? And does it distinguish the approved product from material sold as a research chemical, where the labelled mass is a seller's claim rather than a verified assay?